An interventional study of Drawing and Writing Intervention in Type 1 Diabetes Mellitus (T1DM) and Anxiety, sponsored by Gazi University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 9 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-09-21.
Sponsored by Gazi University · Not applicable, Interventional, and Supportive care
Among 75 studies in Diabetes Mellitus, Type 1 with a site in Turkey — 13 open to participants now, 15 under way, none of them phase 3. Diabetes Mellitus, Type 1 · Turkey.
Among the 75 studies in Diabetes Mellitus, Type 1 with a site in Turkey, this one is the 28th largest by planned enrollment of the 47 interventional ones that give a count, is one of 6 that started in 2026, is one of 37 with no phase, reaches primary completion later than 12 of the 14 other live ones, and was the 73rd registered.
3,754 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →13 of the 75 studies in Diabetes Mellitus, Type 1 with a site in Turkey are open now. Recruiting first, the newest first:
Marmara University · Sites in Turkey
Ages 8–12
KTO Karatay University · Sites in Turkey
Ages 8–12
Biruni University · Sites in Turkey
Ages 9–18
Hoffmann-La Roche · Sites in Turkey, Poland
Ages 18+
Abant Izzet Baysal University · Sites in Turkey
Ages 8–13
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 412 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 258 (63%) stop at 75 or younger; 185 take children under 18; 64 take healthy volunteers.
This study: 9 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
75 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is above the median of 40 across 2,820 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 58 across the 47 interventional studies, 120 across the 28 observational. Of the 59 that completed or were terminated, 7 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 75 have an industry lead sponsor. The 10 most frequent:
Gazi University is the lead sponsor of 551 studies on the registry; 102 are open to participants now.
Gazi University has 3 studies filed under Diabetes Mellitus, Type 1 — fewer than ten, so there is no comparison to draw.
3 of the studies in Diabetes Mellitus, Type 1 with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06704672Hoffmann-La RocheClinical Study to Evaluate the Impact of the Accu-Chek SmartGuide CGM Solution on the Mean Change in Time in Range Compared With Self-Monitoring of Blood Glucose in Participants With Type 1 and Type 2 Diabetes Mellitus | 2026-11-15 |
| NCT07830082Gazi UniversityDrawing and Writing Activities in Adolescents With Type 1 Diabetes | 2026-12-31 |
| NCT07670572Marmara UniversityThink-Find-Solve Activities for Insulin Self-Management in Type 1 Diabetes | 2027-04-15 |
Add all 3 to your calendar (.ics) → With an account.
Among the 75 studies in Diabetes Mellitus, Type 1 with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized controlled trial aims to evaluate the effects of drawing and writing activities on anxiety and positive and negative affect in adolescents with type 1 diabetes. A total of 50 adolescents aged 9 to 18 years will be randomly assigned to either the intervention or the control group. Participants in the intervention group will take part in a five-day online drawing and writing program, while the control group will receive standard care. Anxiety and positive and negative affect will be assessed before and after the intervention using validated questionnaires. The findings may provide evidence for the use of art-based interventions to support the psychological well-being of adolescents with type 1 diabetes.
Type 1 diabetes is a chronic condition that requires lifelong disease management and may adversely affect the emotional well-being of adolescents. In addition to the physical burden of treatment, adolescents with type 1 diabetes may experience anxiety and fluctuations in positive and negative emotions. Creative, non-pharmacological interventions may facilitate emotional expression and promote psychological adjustment during adolescence.
The aim of this randomized controlled trial is to evaluate the effectiveness of a structured drawing and writing program on anxiety and positive and negative affect in adolescents with type 1 diabetes.
The study is designed as a single-blind, parallel-group randomized controlled trial. Eligible adolescents aged 9 to 18 years with type 1 diabetes will be randomly assigned to either the intervention group or the control group. Participants in the intervention group will receive a structured five-day drawing and writing program in addition to standard diabetes care. The intervention is designed to encourage emotional expression through creative activities, including guided drawing, emotion-focused drawing exercises, and brief reflective writing tasks. Each session will last approximately 25 to 30 minutes and will be delivered individually using standardized instructions.
Participants in the control group will receive standard diabetes care without the drawing and writing intervention.
The primary outcome is anxiety. Secondary outcomes include positive affect and negative affect. Outcome measures will be assessed at baseline and immediately after completion of the intervention using validated self-report instruments.
The findings of this study are expected to provide evidence regarding the effectiveness of an art-based psychosocial intervention for improving the emotional well-being of adolescents living with type 1 diabetes.
Inclusion Criteria Adolescents aged 9 to 18 years. Diagnosed with type 1 diabetes mellitus for at least 6 months. Using an insulin infusion pump. Having access to the internet via a smartphone or computer. Able to understand the study procedures and complete the study questionnaires. Providing written informed assent, with written obtained from a parent or legal guardian.
Exclusion Criteria Experience of a major life event (e.g., parental divorce, death of a family member, or relocation) within the past 6 months.
Use of a continuous glucose monitoring (CGM) sensor. Diagnosis of a severe psychiatric disorder. Participation in an art-based education or training program within the past 6 months
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in the experimental group will receive a structured five-day drawing and writing intervention in addition to standard diabetes care. The program consists of individual, guided art-based activities designed to facilitate emotional expression and reflection on living with type 1 diabetes. Each daily session will last approximately 25-30 minutes and includes drawing, emotion-focused creative activities, and brief reflective writing. All sessions will be delivered individually by the same trained researcher using standardized instructions.
Other: Drawing and Writing Intervention
Participants in the control group will receive standard diabetes care routinely provided at the pediatric endocrinology clinic. They will not participate in the structured drawing and writing intervention during the study period. Outcome assessments will be conducted at the same time points as in the intervention group.
Participants assigned to the intervention group will receive a structured drawing and writing intervention in addition to standard diabetes care. The intervention consists of five individual sessions conducted over five consecutive days, each lasting approximately 25-30 minutes. Guided activities include drawing, emotion-focused art exercises, and brief reflective writing designed to facilitate emotional expression and coping with type 1 diabetes. All sessions are delivered individually by the same trained researcher using standardized instructions.
State Anxiety
State anxiety will be assessed using the State Anxiety Inventory for Children (SAIC). The SAIC is a validated self-report instrument consisting of 20 items scored on a 3-point Likert scale. Total scores range from 20 to 60, with higher scores indicating greater state anxiety.
Time frame: Baseline (Day 1, before the intervention) and immediately after completion of the intervention (Day 5).
State Anxiety
State anxiety will be assessed using the State Anxiety Inventory for Children (SAIC). Scores range from 20 to 60, with higher scores indicating greater state anxiety.
Time frame: Baseline and Day 5 (immediately after completion of the intervention)
Positive Affect
Positive affect will be assessed using the Short Positive and Negative Affect Scale for Children (PANAS-C-SF). Higher scores indicate greater positive affect.
Time frame: Baseline and Day 5 (immediately after completion of the intervention)
Negative Affect
Negative affect will be assessed using the Short Positive and Negative Affect Scale for Children (PANAS-C-SF). Higher scores indicate greater negative affect.
Time frame: Baseline and Day 5 (immediately after completion of the intervention)
Plan to share: No — Individual participant data will not be made publicly available because of privacy and confidentiality considerations and the lack of participant consent for public data sharing.
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Dec 2026, 8 months after the start.
Of 845 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 38. This study's planned 8 months is below that.
Counting every sponsor, half of 950 studies reached it within 18 months; a quarter within 9 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.